GSK gets research-stage cancer project from Vernalis
Only a couple months after signing a new oncology collaboration with Servier, UK biotech Vernalis PLC has forged another deal in this therapeutic area, this time with GlaxoSmithKline, which has received an option to Vernalis' research program in cancer.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.